The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative effectiveness of combination first-line therapies for metastatic renal cell carcinoma (mRCC).
 
Rebecca C. Shay
No Relationships to Disclose
 
Andrew Nicklawsky
No Relationships to Disclose
 
Elaine Tat Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Immunomedics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Decibel Therapeutics